Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Donato

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Oncotarget|September 17, 2015
Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemiasDany A Curi, Elspeth M Beauchamp, Gavin T Blyth, et al.
Journal of the National Cancer Institute|June 26, 2008
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinaseJi Wu, Feng Meng, Ling-Yuan Kong, et al.
Nature Communications|February 16, 2017
Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanomaHarish Potu, Luke F Peterson, Malathi Kandarpa, et al.
Cancer Research|January 28, 2004
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemiaNicholas J Donato, Ji Y Wu, Jonathan Stapley, et al.
Antimicrobial Agents and Chemotherapy|May 4, 2016
Anti-infective Activity of 2-Cyano-3-Acrylamide Inhibitors with Improved Drug-Like Properties against Two Intracellular PathogensKarla D Passalacqua, Marie-Eve Charbonneau, Nicholas J Donato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancerRalph G Zinner, John Nemunaitis, Irene Eiseman, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cellsNathalie Carayol, Eliza Vakana, Antonella Sassano, et al.
The American Journal of Pathology|March 2, 2006
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse modelJose G Trevino, Justin M Summy, Donald P Lesslie, et al.
Blood|March 28, 2015
Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignanciesLuke F Peterson, Hanshi Sun, Yihong Liu, et al.
Bioorganic & Medicinal Chemistry|January 25, 2014
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I)Zhenghong Peng, David S Maxwell, Duoli Sun, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Oncotarget|September 17, 2015
Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemiasDany A Curi, Elspeth M Beauchamp, Gavin T Blyth, et al.
Journal of the National Cancer Institute|June 26, 2008
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinaseJi Wu, Feng Meng, Ling-Yuan Kong, et al.
Nature Communications|February 16, 2017
Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanomaHarish Potu, Luke F Peterson, Malathi Kandarpa, et al.
Cancer Research|January 28, 2004
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemiaNicholas J Donato, Ji Y Wu, Jonathan Stapley, et al.
Antimicrobial Agents and Chemotherapy|May 4, 2016
Anti-infective Activity of 2-Cyano-3-Acrylamide Inhibitors with Improved Drug-Like Properties against Two Intracellular PathogensKarla D Passalacqua, Marie-Eve Charbonneau, Nicholas J Donato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancerRalph G Zinner, John Nemunaitis, Irene Eiseman, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cellsNathalie Carayol, Eliza Vakana, Antonella Sassano, et al.
The American Journal of Pathology|March 2, 2006
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse modelJose G Trevino, Justin M Summy, Donald P Lesslie, et al.
Blood|March 28, 2015
Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignanciesLuke F Peterson, Hanshi Sun, Yihong Liu, et al.
Bioorganic & Medicinal Chemistry|January 25, 2014
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I)Zhenghong Peng, David S Maxwell, Duoli Sun, et al.
Pageof 4